FDA Advisory Committee to review Amgen’s biosimilar AmAb candidate

Amgen announces FDA Advisory Committee Meeting to review ABP 501 (biosimilar adalimumab).  FDA has set a Biosimilar User Fee target action date of 25 September 2016.